Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis (Q33687578)

28 July 2017

0 references

1 reference

title

Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis (English)

1 reference

28 July 2017

Wen Wang

1

1 reference

28 July 2017

Xu Zhou

2

1 reference

28 July 2017

Joey S W Kwong

3

1 reference

28 July 2017

Ling Li

4

1 reference

28 July 2017

Youping Li

5

1 reference

28 July 2017

Xin Sun

6

1 reference

28 July 2017

language of work or name

English

0 references

publication date

11 May 2017

1 reference

28 July 2017

1 reference

28 July 2017

volume

7

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

1717

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

copyright license

start time

11 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Pioglitazone: side effect and safety profile

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Rosiglitazone is associated with mortality in chronic hemodialysis patients.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Circulating endothelial progenitor cells and cardiovascular outcomes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Quantifying heterogeneity in a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Diabetic kidney disease: a report from an ADA Consensus Conference.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Prognostic value of coronary vascular endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41598-017-01965-0

Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5431943

Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28496176

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Thiazolidinediones and the risk of edema: a meta-analysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28496176

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/S41598-017-01965-0

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference